191 related articles for article (PubMed ID: 37749304)
1. Effects of iron-based phosphate binders on mortality and cardiovascular events in patients receiving maintenance dialysis.
Tanaka A; Sasaki S; Noma H; Wang J; Onishi Y; Inaguma D
Sci Rep; 2023 Sep; 13(1):16051. PubMed ID: 37749304
[TBL] [Abstract][Full Text] [Related]
2. Effects and safety of iron-based phosphate binders in dialysis patients: a systematic review and meta-analysis.
Zhai CJ; Yu XS; Yang XW; Sun J; Wang R
Ren Fail; 2015 Feb; 37(1):7-15. PubMed ID: 25350834
[TBL] [Abstract][Full Text] [Related]
3. An update on phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a review of safety profiles.
Ogata H; Takeshima A; Ito H
Expert Opin Drug Saf; 2022 Jul; 21(7):947-955. PubMed ID: 35180026
[TBL] [Abstract][Full Text] [Related]
4. Initiation of Sevelamer and Mortality among Hemodialysis Patients Treated with Calcium-Based Phosphate Binders.
Komaba H; Wang M; Taniguchi M; Yamamoto S; Nomura T; Schaubel DE; Smith AR; Zee J; Karaboyas A; Bieber B; Fukagawa M; Tentori F
Clin J Am Soc Nephrol; 2017 Sep; 12(9):1489-1497. PubMed ID: 28724618
[TBL] [Abstract][Full Text] [Related]
5. Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence.
Coyne DW; Sprague SM; Vervloet M; Ramos R; Kalantar-Zadeh K
J Nephrol; 2022 Apr; 35(3):875-888. PubMed ID: 35138627
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis.
Mason MA; Shepler BM
Pharmacotherapy; 2010 Jul; 30(7):741-8. PubMed ID: 20575637
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of iron-based phosphate binders, ferric citrate hydrate and sucroferric oxyhydroxide, in hemodialysis patients.
Yoshida T; Morimoto K; Kaburagi N; Fujino T; Takemitsu TY; Yamashita N; Oya M
Int Urol Nephrol; 2022 Apr; 54(4):861-872. PubMed ID: 34264473
[TBL] [Abstract][Full Text] [Related]
8. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
Patel L; Bernard LM; Elder GJ
Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024
[TBL] [Abstract][Full Text] [Related]
9. Next-generation phosphate binders: focus on iron-based binders.
Nastou D; Fernández-Fernández B; Elewa U; González-Espinoza L; González-Parra E; Sanchez-Niño MD; Ortiz A
Drugs; 2014 Jun; 74(8):863-77. PubMed ID: 24848754
[TBL] [Abstract][Full Text] [Related]
10. Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles.
Locatelli F; Del Vecchio L; Violo L; Pontoriero G
Expert Opin Drug Saf; 2014 May; 13(5):551-61. PubMed ID: 24702470
[TBL] [Abstract][Full Text] [Related]
11. Using iron-based phosphate binders in phosphate reduction and anemia improvement in patients receiving dialysis: a meta-analysis of randomized controlled trials.
Zhu Y; Rao J; Liao X; Ou J; Li W; Xue C
Int Urol Nephrol; 2021 Sep; 53(9):1899-1909. PubMed ID: 33675476
[TBL] [Abstract][Full Text] [Related]
12. The Role of Iron-Based Phosphate Binder in the Treatment of Hyperphosphatemia.
Daoud K; Badran H; Anwar N; Nguyen T
Nephrol Nurs J; 2023; 50(2):140-144. PubMed ID: 37074939
[TBL] [Abstract][Full Text] [Related]
13. Comparative Efficacy and Safety of Phosphate Binders in Hyperphosphatemia Patients With Chronic Kidney Disease.
Yang X; Bai Q; Li Y; Liu H; Guo H; Zhang X
JPEN J Parenter Enteral Nutr; 2018 May; 42(4):766-777. PubMed ID: 28777915
[TBL] [Abstract][Full Text] [Related]
14. [Phosphate binders].
Heeb RM
Med Monatsschr Pharm; 2016 Jun; 39(6):255-60. PubMed ID: 27439258
[TBL] [Abstract][Full Text] [Related]
15. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis.
Jamal SA; Vandermeer B; Raggi P; Mendelssohn DC; Chatterley T; Dorgan M; Lok CE; Fitchett D; Tsuyuki RT
Lancet; 2013 Oct; 382(9900):1268-77. PubMed ID: 23870817
[TBL] [Abstract][Full Text] [Related]
16. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
Ruospo M; Palmer SC; Natale P; Craig JC; Vecchio M; Elder GJ; Strippoli GF
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006023. PubMed ID: 30132304
[TBL] [Abstract][Full Text] [Related]
17. A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY).
Pergola PE; Rosenbaum DP; Yang Y; Chertow GM
J Am Soc Nephrol; 2021 Jun; 32(6):1465-1473. PubMed ID: 33766811
[TBL] [Abstract][Full Text] [Related]
18. Phosphate binders in chronic kidney disease: an updated narrative review of recent data.
Floege J
J Nephrol; 2020 Jun; 33(3):497-508. PubMed ID: 31865608
[TBL] [Abstract][Full Text] [Related]
19. Gut microbiota; an overlooked effect of phosphate binders.
Rahbar Saadat Y; Niknafs B; Hosseiniyan Khatibi SM; Ardalan M; Majdi H; Bahmanpoor Z; Abediazar S; Zununi Vahed S
Eur J Pharmacol; 2020 Feb; 868():172892. PubMed ID: 31870830
[TBL] [Abstract][Full Text] [Related]
20. [Phosphate binders : What are the recent evidences ?].
Bouajila IA; Martin PY; De Seigneux S
Rev Med Suisse; 2017 Feb; 13(551):468-472. PubMed ID: 28714648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
